Development of pediatric orally disintegrating mini-tablets containing atomoxetine hydrochloride- β-cyclodextrin inclusion complex with using experimental design.
Emine Dilek OzyilmazTansel ComogluPublished in: Drug development and industrial pharmacy (2022)
As a conlusion, the novel formulation of ODMTs with ATO/β-CD inclusion complex were succussfully developed for pediatric use.